Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 1.39B |
| Revenue (ttm) | 263.50M |
| Net Income (ttm) | -390.98M |
| Shares Out | 411.96M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,297,312 |
| Open | 3.430 |
| Previous Close | 3.430 |
| Day's Range | 3.330 - 3.495 |
| 52-Week Range | 1.639 - 5.630 |
| Beta | 0.76 |
| Analysts | Buy |
| Price Target | 9.00 (+166.27%) |
| Earnings Date | May 7, 2026 |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients w... [Read more]
Financial Performance
In 2025, Iovance Biotherapeutics's revenue was $263.50 million, an increase of 60.60% compared to the previous year's $164.07 million. Losses were -$390.98 million, 5.05% more than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price target is $9.0, which is an increase of 166.27% from the latest price.
News
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliver...
Iovance Biotherapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Three strategic pillars—commercial growth, pipeline expansion, and operational excellence—are driving strong momentum, with Amtagvi showing robust real-world efficacy and margin improvements. Pipeline advances in lung cancer, sarcoma, and next-gen TILs, plus global expansion, position the business for significant growth in 2026 and beyond.
What's Going On With Iovance Biotherapeutics Stock On Friday?
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) stock is trading higher on Friday, with no news to justify the movement.
Iovance Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Strong Q4 and full-year financials were driven by AMTAGVI adoption and operational improvements, with a focus on expanding treatment center networks and advancing a robust pipeline. Key clinical milestones are expected in lung cancer and sarcoma, with next-generation TIL therapies in development.
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy
Iovance Biotherapeutics (NASDAQ: IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarc...
Iovance Biotherapeutics Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw 61% revenue growth, record gross margins, and strong AMTAGVI adoption. Pipeline advances include FDA Fast Track for lifileucel in lung cancer and positive sarcoma data, with global expansion and further revenue growth expected in 2026.
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE N...
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate 52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate
Iovance Biotherapeutics Earnings Call Transcript: Q3 2025
Q3 revenue rose 13% sequentially to $68M, with gross margin improving to 43% due to cost reductions. Amtagvi and Proleukin sales drove growth, and strong clinical data in NSCLC support future expansion. Revenue guidance of $250–300M for 2025 is reaffirmed.
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stoc...
Iovance Biotherapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Amtagvi, the first FDA-approved T-cell therapy for solid tumors, is expanding into new indications and earlier lines of therapy, with strong clinical data and significant market potential. Operational improvements and a recent restructuring aim to boost margins and accelerate profitability.
Iovance Biotherapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Revenue guidance reset to $250–$300 million with strong Q2 growth and operational streamlining. Real-world data shows high response rates, and pipeline progress includes pivotal lung and endometrial cancer trials, with regulatory strategies evolving for U.S. and E.U. markets.
Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy
Iovance Biotherapeutics Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 22% sequentially to $60M, driven by record Amtagvi infusions and strong demand. Strategic restructuring is set to deliver $100M+ in annual savings and margin improvement, with guidance reaffirmed at $250–$300M for the year.
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reite...
Here's why Iova stock surged 32% today and why the rally might not be over
Iova stock rallied 32% on Wednesday, snapping out of a long, sluggish stretch that had frustrated investors for months. The Iovance Biotherapeutics (NASDAQ: IOVA) shares have been stuck in a tight ran...
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
LOS ANGELES , July 14, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violatio...
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focu...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.
SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...